Italy's €938,000 Lab Contract Attracted One Bid - But the Hospital Chose No Winner

A northern Italian health authority received exactly one tender for a €938,000 laboratory quality control contract and closed the competition anyway, citing only "other" as its reason.

Standfirst

Azienda Ulss 2 Marca Trevigiana, the public health authority covering the Treviso area of Veneto, asked the market for an external quality control service to check the reliability of its infectious disease blood testing. One company answered. The health authority still declined to award the contract, recording its reason simply as "other", a more puzzling outcome than a tender that draws no bids at all and one this notice leaves largely unexplained.

Introduction

Most stories about a failed public tender involve nobody showing up. This one is different and more interesting for it: a company did show up, submitted a tender and still walked away without a contract.

This notice covers a single lot within a much larger Italian laboratory diagnostics tender, the same 23 lot, €215 million programme run by Azienda Ulss 2 Marca Trevigiana that has already produced at least one zero bid outcome elsewhere in its portfolio. This time, the story is not an absence of interest. It is a health authority that had an offer on the table and turned it down regardless.

Why This Contract Matters

Quality control might sound like a back office formality, but in a hospital laboratory it is the mechanism that lets clinicians trust a test result enough to act on it. A third party quality control service checks a lab's infectious disease testing against an independent standard, catching drift or error before it reaches a patient's diagnosis.

When a contract for that kind of service fails to close, even with a willing bidder in hand, it leaves a genuine gap in a hospital's quality assurance chain, one the health authority now has to resolve and one this notice does not explain in any detail.

Contract Timeline

• 1 October 2025, The estimated start date recorded for the lot, well before this result notice was even dispatched.
• 8 July 2026, The result notice was dispatched for publication.
• 9 July 2026, The notice was published in the Official Journal of the EU (OJ S 130/2026).

As with a related lot from the same parent tender covered previously, the gap between the planned 2025 start date and this 2026 publication indicates the lot sat unresolved for many months before the health authority formally closed it.

Contract Overview

This notice covers Lot 15 of a much larger, 23 lot open tender run by Azienda Ulss 2 Marca Trevigiana to secure "Laboratory and Microbiology Diagnostic Systems" as a bundled equipment and service package, with an overall estimated value across all 23 lots of €215,480,016.60. Lot 15 specifically sought a third party internal quality control service for seroinfectivology, external verification of a laboratory's infectious disease serology testing, estimated at €937,900 over an 84 month term.

One tender was submitted for this lot. Despite that, the health authority recorded the outcome as "no winner was chosen and the competition is closed," giving the reason as "other", a generic, non specific justification category that does not itself explain why a single, apparently eligible bid failed to result in an award.

Key Contract Details

Project Scope

Lot 15 covers third party quality control for seroinfectivology testing, the branch of laboratory medicine that detects infections through markers in blood serum, covering conditions such as hepatitis, HIV and other transmissible infections. A third party quality control provider supplies an independent benchmark sample set and cross checks a hospital laboratory's results against it, flagging any drift in accuracy before it can affect a real patient diagnosis.

The lot's scope bundles several elements into one service contract: the computer equipment and software needed to manage the quality control programme, consumable materials for testing, full risk technical assistance, staff training and scientific support and IT connectivity linking the quality control system to the laboratory's existing instruments, middleware or laboratory information system. As with other lots in the same parent tender, the contract carried built in flexibility: an option to extend by up to 24 months beyond the base term, a further possible 6 month extension after that and a standard Italian public contract clause allowing quantities to flex up or down by as much as a fifth of the contract's value during execution.

About the Contracting Authority

Azienda Ulss 2 Marca Trevigiana is the public health authority responsible for health services across the Treviso area of Italy's Veneto region, classified in the notice as a body governed by public law with health as its main activity. It ran this tender, like the rest of its 23 lot diagnostics programme, through the Veneto region's SINTEL e procurement platform, operated by the regional purchasing agency ARIA S.p.A.

This is the same health authority behind a separately reported zero bid outcome on two tuberculosis related diagnostic lots within the same parent programme, making this now at least the second lot in the same tender where the health authority has failed to secure a working contract on its first attempt.

About the Organisations Involved

Azienda Ulss 2 Marca Trevigiana, Buyer

Based in Treviso, the health authority designed this lot's technical and scoring requirements, received the single tender submitted and ultimately decided not to proceed with an award. It is now responsible for deciding whether to retender the lot, adjust its requirements or pursue quality control services through another route.

Tribunale Amministrativo Regionale per il Veneto, Review Organisation

The Regional Administrative Court for Veneto, based in Venice, is the designated review body for this procedure. There is no indication in the notice that any formal review or appeal was lodged in connection with this lot's non award.

There is no winning supplier to report for this lot. Despite one tender being received, no company holds a contract and the notice does not name the tenderer that came forward, since that level of detail is only recorded for winning bids.

Procurement Analysis

The single most significant fact in this notice is what it does not say: a tender was received, yet the health authority declined to award the contract and the justification field simply reads "Other", one of the least informative categories available under the EU's standard non award reason codes. Unlike a zero bid outcome, where the explanation is self evident, this result implies an active decision by the buyer not to proceed with the one offer it had, for reasons the notice does not detail.

Plausible explanations consistent with EU procurement practice include the sole tender being found non compliant with the technical specification, exceeding the authority's budget ceiling, failing an administrative eligibility check or the authority choosing to cancel the lot for its own organisational reasons, a possibility explicitly reserved in the parent tender's own terms, which allow the health authority to suspend, modify or annul the procedure, including if a regional or national central purchasing body activates an overlapping framework during the tender's life. The notice does not indicate which, if any, of these applied here and the contracting authority has not disclosed further detail.

The lot's award criteria, quality weighted at 70%, cost at 30%, match the same heavily quality focused formula used elsewhere in this parent tender, again suggesting the health authority prioritises technical reliability and service quality in laboratory critical categories over the lowest available price.

Additional Procurement Facts

This lot carries the same standard contractual architecture as its sibling lots in the same 23 lot programme: an 84 month base term, options to extend by up to 24 months and then a further 6 months and a quinto d'obbligo clause allowing the health authority to adjust contract volume by up to one fifth without the supplier being able to terminate. The tender also used Italy's "inversione procedimentale" evaluation technique, assessing technical and economic bids before verifying administrative eligibility, a procedural detail carried over from the parent tender's terms.

Market & Industry Perspective

Third party laboratory quality control services sit in a specialised corner of the diagnostics market, typically served by a small number of established providers who supply standardised reference samples and comparative scoring programmes to hospital laboratories across multiple countries. A single bid outcome in this category is not inherently alarming, narrow technical categories often attract only one or two capable providers, but a single bid still failing to convert into an award is a more unusual and specific signal, suggesting either a mismatch between the health authority's requirements and what the market offered or a compliance issue specific to that one bid.

Combined with the previously reported zero bid outcome on two tuberculosis related lots in the same parent tender, this result adds to a pattern worth watching: a meaningful share of this particular hospital's specialised diagnostics tender appears to be struggling to convert into signed contracts on the first attempt, across more than one distinct product category.

Economic Significance

At an estimated €937,900 over the contract's base term, this is one of the smaller individual lots within the parent tender's overall €215 million scope, but the underlying service, verifying the accuracy of infectious disease testing, carries clinical significance well beyond its price tag. An unresolved quality control contract does not stop testing from happening; it does mean the hospital either continues under a prior arrangement, if one exists or operates without the specific independent verification this lot was meant to provide.

For the broader pattern across this health authority's tender, repeated non award outcomes across different lots may point to a specification or budgeting approach that is not consistently matching what the market can deliver, a dynamic worth monitoring as the remaining lots in the same 23 lot programme are progressively reported.

Future Procurement Opportunities

The health authority will most likely need to retender Lot 15, either with the same requirements or with adjustments informed by whatever caused the sole tender to fail. Providers of third party laboratory quality control services who did not bid this time or who bid and were not successful, have a clear opening to engage with the health authority ahead of any retender to understand what specification or eligibility issue may have been at play.

The broader 23 lot parent tender continues to generate individual lot results over time; suppliers active in Italian hospital diagnostics should continue tracking this specific procedure (ID 3677) for further outcomes, particularly given the pattern of non award results already recorded across at least three of its lots.

Opportunities for Suppliers

• Engage directly with the health authority before any retender of Lot 15, since a specific, undisclosed issue evidently affected the sole tender received and early dialogue may reveal what a compliant future bid needs to address.
• Watch this parent tender closely for further non award patterns. With at least three lots now failing to result in a signed contract on the first pass, suppliers positioning for the retenders may find a genuinely reduced competitive field.
• Specialist quality control and proficiency testing providers should consider this a live gap in a major Italian public hospital's diagnostics programme, worth pursuing once a retender is published.

What Businesses Should Watch

Watch for a retender notice covering Lot 15 and note whether the specification or budget changes meaningfully from this attempt, which would suggest the health authority identified a specific mismatch with what the market previously offered.

Watch the outcome of the remaining lots in the same 23 lot procedure as they are published, to establish whether non award outcomes are becoming a recurring feature of this particular tender or remain isolated to a handful of specialised categories.

Watch for any public explanation from the health authority regarding its "other" justification; while none is required under EU procurement rules, suppliers with a direct relationship to the authority may be able to obtain informal clarification ahead of a retender.

TendersOnTime Procurement Intelligence

This notice is a useful reminder that "no winner chosen" does not always mean "no interest." A tender can attract a bid, clear an initial hurdle of market interest and still fail to produce a contract and under current EU reporting standards, a buyer can record that outcome under a generic "other" category without further public explanation. For market analysts and competitors alike, that is a meaningfully less informative result than either a clean award or a documented zero bid closure and it deserves more scrutiny rather than less.

Set alongside the same health authority's separately reported zero bid outcome on two tuberculosis related lots within the same 23 lot tender, this result strengthens a pattern worth watching: whatever combination of specification design, budget calibration or administrative process this authority is using across its diagnostics programme, it appears to be struggling to convert several distinct, specialised lots into signed contracts on the first attempt. That is a more structural signal than any single lot result on its own and it is the kind of pattern that only becomes visible by tracking a parent tender's full set of lot level outcomes rather than reading individual notices in isolation.

For suppliers, the opportunity here is to treat this as market intelligence rather than a dead end. A buyer that has struggled to award a specific lot twice over, first through a zero bid outcome and now through a single failed bid elsewhere in the same tender, is a buyer likely to be receptive to supplier engagement ahead of its next attempt.

Supplier Takeaways

• Contact Azienda Ulss 2 Marca Trevigiana directly if your organisation provides third party laboratory quality control or proficiency testing services, even before a retender of Lot 15 is published.
• Track the full set of lot level outcomes from procedure ID 3677 rather than any single notice, since a pattern of non award results across multiple lots is emerging within this specific tender.
• Prepare technical and administrative documentation carefully for any retender, given that an apparently qualified sole bidder still failed to secure this contract for reasons the notice does not disclose.
• Treat repeated non award outcomes at a single buyer as a signal of specification or process issues worth raising directly with the contracting authority, rather than assuming a lack of market interest.

Key Takeaways

• Azienda Ulss 2 Marca Trevigiana received one tender for Lot 15 of its 23 lot laboratory diagnostics programme, covering third party quality control for infectious disease serology testing and still closed the competition without an award.
• The estimated value of the lot was €937,900 over an 84 month base term, with standard renewal and extension options.
• The buyer's stated reason for not awarding was simply "Other," with no further detail disclosed in the notice.
• Award criteria were weighted 70% quality to 30% cost, consistent with the pattern seen elsewhere in the same parent tender.
• This is at least the third lot within the same 23 lot, €215 million procedure to end without a signed contract on its first attempt.

Conclusion

A tender that draws no bids tells a simple story. A tender that draws exactly one bid and still ends without a contract, tells a more complicated one and this notice leaves most of that complication unresolved. For a hospital that already has one documented zero bid outcome elsewhere in the same large diagnostics programme, this second non award result is worth watching closely as this tender's remaining lots continue to come to light.

Frequently Asked Questions

Q1. Why would a hospital reject its only bid for a contract?

The notice does not say. Common reasons in EU procurement practice include a bid failing to meet technical specifications, exceeding budget expectations, an administrative eligibility issue or the buyer choosing to cancel the lot for its own organisational reasons, but none of these is confirmed here.

Q2. What does "the reason why a winner was not chosen: Other" actually mean?

It is one of several standard categories EU procurement notices use to record why a lot was not awarded. "Other" is the least specific of these categories and does not itself explain the underlying cause.

Q3. What is third party quality control in a hospital laboratory?

It is an independent service that checks a laboratory's test results, in this case for infectious disease serology, against a benchmark standard, helping ensure the lab's equipment and processes remain accurate over time.

Q4. Is this related to the health authority's other reported tender problems?

Yes. This is part of the same 23 lot, €215 million parent tender in which two other lots covering tuberculosis diagnostics previously closed with zero bids received. This lot's failure to convert its single bid into a contract adds a further non award result to the same procedure.

Q5. Will this lot be retendered?

The notice does not confirm this, but it is the most likely outcome given the health authority's ongoing need for the quality control service this lot was meant to provide.

Q6. Was this contract financed by the EU?

No. The lot is confirmed as not financed with EU funds and not covered by the WTO Government Procurement Agreement.

Q7. How long would the contract have run?

The base term was 84 months, with an option to extend by up to 24 months and a further possible 6 month extension after that.

Source: EU Official Journal, Contract Award Notice 472148-2026, OJ S 130/2026, published 9 July 2026. Contracting authority: Azienda Ulss 2 Marca Trevigiana.